These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34945109)

  • 1. Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.
    Welz A; Koba M; Kośliński P; Siódmiak J
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.
    Welz A; Koba M; Kośliński P; Siódmiak J
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazine derivatives as dangerous abused compounds.
    Welz A; Koba M
    Acta Pharm; 2020 Dec; 70(4):423-441. PubMed ID: 32412428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples.
    Dickson AJ; Vorce SP; Holler JM; Lyons TP
    J Anal Toxicol; 2010 Oct; 34(8):464-9. PubMed ID: 21819791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
    Peters FT; Schaefer S; Staack RF; Kraemer T; Maurer HH
    J Mass Spectrom; 2003 Jun; 38(6):659-76. PubMed ID: 12827635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel analytical method of TFMPP and mCPP in fluids of drug addicts using LLE-GC/NPD.
    Ren Y; Du J; Du X; Xin G; Chang J; Zhou H; Hao H
    Technol Health Care; 2019; 27(S1):67-84. PubMed ID: 31045528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs.
    Bell C; George C; Kicman AT; Traynor A
    Drug Test Anal; 2011; 3(7-8):496-504. PubMed ID: 21744513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine.
    Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nishikawa M; Nakajima K; Tsuchihashi H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(2):315-22. PubMed ID: 15833296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS.
    Vorce SP; Holler JM; Levine B; Past MR
    J Anal Toxicol; 2008; 32(6):444-50. PubMed ID: 18652752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperazine compounds as drugs of abuse.
    Arbo MD; Bastos ML; Carmo HF
    Drug Alcohol Depend; 2012 May; 122(3):174-85. PubMed ID: 22071119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum.
    Wohlfarth A; Weinmann W; Dresen S
    Anal Bioanal Chem; 2010 Apr; 396(7):2403-14. PubMed ID: 20069283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone.
    Staack RF; Maurer HH
    J Anal Toxicol; 2003; 27(8):560-8. PubMed ID: 14670134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-dependent inhibition of the human α1β2γ2 GABAA receptor by piperazine derivatives: A novel mode of action.
    Hondebrink L; Hermans EJ; Schmeink S; van Kleef RG; Meulenbelt J; Westerink RH
    Neurotoxicology; 2015 Dec; 51():1-9. PubMed ID: 26344803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector.
    Bishop SC; McCord BR; Gratz SR; Loeliger JR; Witkowski MR
    J Forensic Sci; 2005 Mar; 50(2):326-35. PubMed ID: 15813543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine.
    Schep LJ; Slaughter RJ; Vale JA; Beasley DM; Gee P
    Clin Toxicol (Phila); 2011 Mar; 49(3):131-41. PubMed ID: 21495881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of designer drugs of abuse.
    Staack RF; Maurer HH
    Curr Drug Metab; 2005 Jun; 6(3):259-74. PubMed ID: 15975043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP.
    Elliott S; Smith C
    J Anal Toxicol; 2008 Mar; 32(2):172-7. PubMed ID: 18334102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans.
    Souto C; Göethel G; Peruzzi CP; Cestonaro LV; Garcia I; Ávila DS; Eifler-Lima V; Carmo H; Bastos ML; Garcia SC; Arbo MD
    J Appl Toxicol; 2020 Mar; 40(3):363-372. PubMed ID: 31755144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis.
    Dias da Silva D; Silva MJ; Moreira P; Martins MJ; Valente MJ; Carvalho F; Bastos ML; Carmo H
    Arch Toxicol; 2017 Mar; 91(3):1413-1430. PubMed ID: 27358233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market.
    de Boer D; Bosman IJ; Hidvégi E; Manzoni C; Benkö AA; dos Reys LJ; Maes RA
    Forensic Sci Int; 2001 Sep; 121(1-2):47-56. PubMed ID: 11516887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.